公开(公告)号：US20110034413A1

公开(公告)日：2011-02-10

申请号：US12676709

申请日：2008-08-08

申请人： Narendra Shriram Joshi ,  Pawan Aggarwal ,  Vitthalbhai Ketan Hirpara ,  Manu Jaggi ,  Anu Singh ,  Anshumali Awasthi ,  Ritu Verma

发明人： Narendra Shriram Joshi ,  Pawan Aggarwal ,  Vitthalbhai Ketan Hirpara ,  Manu Jaggi ,  Anu Singh ,  Anshumali Awasthi ,  Ritu Verma

IPC分类号： A61K31/7008 ,  C07D311/30 ,  C07H5/06 ,  A61K31/352 ,  A61P35/00

CPC分类号： C07D311/30

摘要： The present invention provides novel Quercetin derivatives of formula (I) and pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1 is hydrogen, benzyl or substituted benzyl; R2 is hydrogen, benzyl or substituted benzyl, linear or branched (C1-C6) alkyl, substituted alkyl, aryl, substituted aryl, heterocycle and substituted heterocycle, useful for treatment of various disorders including cancer, multi-drug resistant cancers, viral infections etc. The invention also provides a process for the preparation of compounds of formula (I) and pharmaceutical compositions comprising the same.

摘要翻译： 本发明提供新的式（I）槲皮素衍生物及其药学上可接受的盐，水合物和溶剂合物，其中R1是氢，苄基或取代的苄基; R2是氢，苄基或取代的苄基，直链或支链（C1-C6）烷基，取代的烷基，芳基，取代的芳基，杂环和取代的杂环，可用于治疗各种疾病，包括癌症，多药耐药性癌症，病毒感染等 本发明还提供了制备式（I）化合物和包含其的药物组合物的方法。

公开(公告)号：US20070093422A1

公开(公告)日：2007-04-26

申请号：US11643342

申请日：2006-12-21

申请人： Rama Mukherjee ,  Anand Burman ,  Anu Singh ,  Manu Jaggi ,  Sudhanand Prasad ,  Sarjana Dutt

发明人： Rama Mukherjee ,  Anand Burman ,  Anu Singh ,  Manu Jaggi ,  Sudhanand Prasad ,  Sarjana Dutt

IPC分类号： A61K38/10 ,  C07K7/06

CPC分类号： A61K38/08 ,  A61K2300/00

摘要： The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.

摘要翻译： 本发明涉及可用于治疗癌症的肽的组合。 肽组合竞争在质膜上特异性神经肽的结合，从而改变涉及细胞增殖的关键细胞内分子的水平，导致广谱的抗癌活性。 本发明还涉及含有这些肽类似物的组合的药物组合物。

公开(公告)号：US20060159783A1

公开(公告)日：2006-07-20

申请号：US11219482

申请日：2005-09-02

申请人： Rama Mukherjee ,  Dhiraj Khattar ,  Manu Jaggi ,  Anu Singh ,  Mukesh Kumar ,  Honey Bala

发明人： Rama Mukherjee ,  Dhiraj Khattar ,  Manu Jaggi ,  Anu Singh ,  Mukesh Kumar ,  Honey Bala

IPC分类号： A61K36/906

CPC分类号： A61K31/56 ,  A61K36/725

摘要： This invention relates to an orally effective herbal extract-based composition having broad-spectrum anticancer activity, more specifically a method of treating, inhibiting and/or preventing malignant tumors of the colon, intestine, stomach, breast, melanoma, glioblastoma, lung, cervix, ovary, prostate, oral cavity, larynx, liver, pancreas, kidney, bladder, endothelial cells, leukemia and myeloma using a herbal extract of Zizyphus, rich in betulinic acid. An advantage of the extract is that the betulinic acid has low systemic toxicity. The extract inhibits Protein Kinase C activity of cancer cells and induces apoptosis.

摘要翻译： 本发明涉及具有广谱抗癌活性的口服有效的草药提取物组合物，更具体地，涉及治疗，抑制和/或预防结肠，肠，胃，乳腺，黑素瘤，成胶质细胞瘤，肺，子宫颈恶性肿瘤的方法 ，卵巢，前列腺，口腔，喉，肝，胰腺，肾，膀胱，内皮细胞，白血病和骨髓瘤，使用梓属的草药提取物，富含桦木酸。 提取物的优点是桦木酸具有低的全身毒性。 提取物抑制癌细胞的蛋白激酶C活性并诱导细胞凋亡。

公开(公告)号：US20070203248A1

公开(公告)日：2007-08-30

申请号：US11789974

申请日：2007-04-26

申请人： Rama Mukherjee ,  Anu Singh ,  Kakali Dutta ,  G.C. Maickap ,  Anil Shukla ,  Dhiraj Khattar ,  Anand Burman

发明人： Rama Mukherjee ,  Anu Singh ,  Kakali Dutta ,  G.C. Maickap ,  Anil Shukla ,  Dhiraj Khattar ,  Anand Burman

IPC分类号： A61K31/137

CPC分类号： A61K31/4045 ,  A61K31/00 ,  A61K31/704 ,  A61K2300/00

摘要： The invention relates to pharmaceutical compositions comprising 5-Methoxytryptamine or a salt thereof for the prevention and/or treatment of mammalian cardiac tissue damage. 5-Methoxytryptamine and the salts thereof act as free radical scavengers in the prevention and/or treatment of mammalian cardiac tissue damage mediated by free oxygen radicals.

摘要翻译： 本发明涉及包含5-甲氧基色胺或其盐的药物组合物，用于预防和/或治疗哺乳动物心脏组织损伤。 5-甲氧基色胺及其盐作为自由基清除剂，用于预防和/或治疗由游离氧自由基介导的哺乳动物心脏组织损伤。

公开(公告)号：US20050020666A1

公开(公告)日：2005-01-27

申请号：US10627398

申请日：2003-07-25

申请人： Rama Mukherjee ,  Anu Singh ,  Kakali Dutta ,  G.C Maickap ,  Anil Shukla ,  Dhiraj Khattar ,  Anand Burman

发明人： Rama Mukherjee ,  Anu Singh ,  Kakali Dutta ,  G.C Maickap ,  Anil Shukla ,  Dhiraj Khattar ,  Anand Burman

IPC分类号： A61K31/00 ,  A61K31/4045 ,  A61K31/704 ,  A61P9/10 ,  A61P39/06 ,  A61K31/405

CPC分类号： A61K31/4045 ,  A61K31/00 ,  A61K31/704 ,  A61K2300/00

摘要： The invention relates to pharmaceutical compositions comprising 5-Methoxytryptamine or a salt thereof for the prevention and/or treatment of mammalian cardiac tissue damage. 5-Methoxytryptamine and the salts thereof act as free radical scavengers in the prevention and/or treatment of mammalian cardiac tissue damage mediated by free oxygen radicals.

摘要翻译： 本发明涉及包含5-甲氧基色胺或其盐的药物组合物，用于预防和/或治疗哺乳动物心脏组织损伤。 5-甲氧基色胺及其盐作为自由基清除剂，用于预防和/或治疗由游离氧自由基介导的哺乳动物心脏组织损伤。

公开(公告)号：US20180285982A1

公开(公告)日：2018-10-04

申请号：US15472266

申请日：2017-03-28

申请人： Yogish Pai ,  Anu Singh ,  Steve George Goyette ,  Ram Shamanna ,  Peter Thomas ,  Madhusudhanan Dharumaraj

发明人： Yogish Pai ,  Anu Singh ,  Steve George Goyette ,  Ram Shamanna ,  Peter Thomas ,  Madhusudhanan Dharumaraj

IPC分类号： G06Q40/00 ,  G06Q10/10 ,  G06Q10/06 ,  G06F9/44

摘要： A system for account mapping includes functionality for obtaining more than one labeled accounts labeled by more than one accountant; pre-processing more than one labeled accounts using natural language processing, using the more than one pre-processed labeled accounts to train an account mapping model that performs multinomial classification; receiving an account name from an accounting application where the account name includes a text label for an account included in a chart of accounts; generating an account mapping by applying the account mapping model to the account name, where the account mapping includes a type of the account, a sub-type of the account, a code, and a series associated with an accounting form; returning the account mapping to the accounting application through an Application Programming Interface (API); and receiving a corrected account mapping from an accountant and using the corrected account mapping as a new text label to incrementally update the account mapping model.